- Home
- NSP vs ACAD Comparison
NSP vs ACAD Comparison
Compare NSP & ACAD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NSP
- ACAD
- Stock Information
- Founded
- NSP 1986
- ACAD 1993
- Country
- NSP United States
- ACAD United States
- Employees
- NSP 4500
- ACAD N/A
- Industry
- NSP Professional Services
- ACAD Biotechnology: Pharmaceutical Preparations
- Sector
- NSP Consumer Discretionary
- ACAD Health Care
- Exchange
- NSP Nasdaq
- ACAD Nasdaq
- Market Cap
- NSP 3.2B
- ACAD 2.8B
- IPO Year
- NSP 1997
- ACAD 2004
- Fundamental
- Price
- NSP $78.93
- ACAD $14.73
- Analyst Decision
- NSP Hold
- ACAD Buy
- Analyst Count
- NSP 4
- ACAD 16
- Target Price
- NSP $93.67
- ACAD $23.93
- AVG Volume (30 Days)
- NSP 484.5K
- ACAD 1.8M
- Earning Date
- NSP 04-30-2025
- ACAD 05-07-2025
- Dividend Yield
- NSP 3.04%
- ACAD N/A
- EPS Growth
- NSP N/A
- ACAD N/A
- EPS
- NSP 2.39
- ACAD 1.36
- Revenue
- NSP $6,581,000,000.00
- ACAD $957,797,000.00
- Revenue This Year
- NSP $5.91
- ACAD $13.07
- Revenue Next Year
- NSP $7.79
- ACAD $9.88
- P/E Ratio
- NSP $32.91
- ACAD $10.83
- Revenue Growth
- NSP 1.47
- ACAD 31.85
- 52 Week Low
- NSP $68.79
- ACAD $13.40
- 52 Week High
- NSP $109.80
- ACAD $20.68
- Technical
- Relative Strength Index (RSI)
- NSP 37.45
- ACAD 38.07
- Support Level
- NSP $77.81
- ACAD $14.34
- Resistance Level
- NSP $86.02
- ACAD $15.18
- Average True Range (ATR)
- NSP 3.37
- ACAD 0.80
- MACD
- NSP -0.66
- ACAD -0.02
- Stochastic Oscillator
- NSP 8.74
- ACAD 38.22
About NSP Insperity Inc.
Insperity Inc is a company that provides a wide range of human resources and business solutions designed to help businesses improve their performance. Small and midsize enterprises are the company's primary target customers. Majority of the company's products are offered through the company's Workforce Optimization and Workforce Synchronization solutions, which comprise various human resource functions, such as payroll and employment administration, employee benefits and compensation, government compliance, performance management, training and development services, and human capital management. The company generates all of its revenue in the United States.
About ACAD ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It has two core franchises in neuroscience and neuro-rare diseases. The neuroscience franchise is anchored by its commercial product NUPLAZID (pimavanserin), which is used for the treatment of hallucinations and delusions associated with Parkinson's Disease Psychosis (PDP). The neuro-rare disease franchise is anchored by the commercial product DAYBUE, which is used for the treatment of Rett syndrome. In addition, the company has various product candidates under development in different stages, including ACP-204, ACP-101, ACP-211, ACP-711, ACP-2591, etc.